abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
1093: TBII (Thyrotropin-Binding Inhibitory Immunoglobulin) Print View
TBII RIA  < 17  %Inhibition 

PRIMARY
1 Serum 1 (0.2) mL   Refrigerated - 7 Day(s)/Frozen - 2 Month(s)/Room Temperature - 24 Hour(s)  
ALTERNATE

Used in diagnosis of hyperthyroidism and Graves' disease. The Thyrotropin Receptor Autoantibody (TRAB) Assay has utility in the differential diagnosis of Graves disease versus toxic nodular goiter. A low-positive TRAB (15-60) upon initial diagnosis is indicative of a high likelihood that a 6-18 month course of anti-thyroid drug medication will result in remission of Graves disease. Conversely, a high-positive TRAB (>80) upon initial diagnosis indicates a low likelihood of disease remission following anti-thyroid therapy. Studies show that 83% of patients with detectable receptor antibody activity (i.e., an elevated TRAB) at the end of a twelve month course of anti-thyroid drug therapy subsequently relapse. Non-elevated TRAB concentrations after twelve months of drug treatment predict remission in 89% of patients at 1 year and in 81% at 3 years after drug withdrawal. In the most current studies, the frequency of an elevated TRAB in patients with confirmed Graves disease ranges from 94-100%.
Setup Schedule
Monday

Reported (Analytical Time)
Same day

CPT Code
83519

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.






1996 - 2017 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database